Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 169

1.

Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.

Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA.

Pharmgenomics Pers Med. 2018 Jun 29;11:113-119. doi: 10.2147/PGPM.S160763. eCollection 2018.

2.

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole.

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA.

Pharmgenomics Pers Med. 2018 Jun 18;11:107-112. doi: 10.2147/PGPM.S159708. eCollection 2018.

3.

Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population.

Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J.

Pharmgenomics Pers Med. 2018 Jun 8;11:95-106. doi: 10.2147/PGPM.S165805. eCollection 2018.

4.

Emerging biomarkers in the diagnosis of prostate cancer.

Filella X, Fernández-Galan E, Fernández Bonifacio R, Foj L.

Pharmgenomics Pers Med. 2018 May 16;11:83-94. doi: 10.2147/PGPM.S136026. eCollection 2018. Review.

5.

Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation.

Asleh R, Briasoulis A, Berinstein EM, Wiener JB, Palla M, Kushwaha SS, Levy AP.

Pharmgenomics Pers Med. 2018 Apr 23;11:71-82. doi: 10.2147/PGPM.S159454. eCollection 2018.

6.

Budget impact model for oncopharmacogenetics from the perspective of mandatory basic health insurance in Switzerland using the example of breast cancer.

Szucs TD, Szillat KP, Blozik E.

Pharmgenomics Pers Med. 2018 Apr 23;11:67-69. doi: 10.2147/PGPM.S154368. eCollection 2018.

7.

H3Africa: current perspectives.

Mulder N, Abimiku A, Adebamowo SN, de Vries J, Matimba A, Olowoyo P, Ramsay M, Skelton M, Stein DJ.

Pharmgenomics Pers Med. 2018 Apr 10;11:59-66. doi: 10.2147/PGPM.S141546. eCollection 2018. Review.

8.

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment.

Silvado CE, Terra VC, Twardowschy CA.

Pharmgenomics Pers Med. 2018 Mar 29;11:51-58. doi: 10.2147/PGPM.S108113. eCollection 2018. Review.

9.

Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke.

Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO.

Pharmgenomics Pers Med. 2018 Mar 22;11:43-49. doi: 10.2147/PGPM.S157111. eCollection 2018.

10.

The utility of pharmacogenetic testing to support the treatment of bipolar disorder.

Ielmini M, Poloni N, Caselli I, Espadaler J, Tuson M, Grecchi A, Callegari C.

Pharmgenomics Pers Med. 2018 Mar 16;11:35-42. doi: 10.2147/PGPM.S160967. eCollection 2018.

11.

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

Chen L, Prasad GVR.

Pharmgenomics Pers Med. 2018 Mar 7;11:23-33. doi: 10.2147/PGPM.S107710. eCollection 2018. Review.

12.

Which attributes of whole genome sequencing tests are most important to the general population? Results from a German preference study.

Plöthner M, Schmidt K, Schips C, Damm K.

Pharmgenomics Pers Med. 2018 Feb 14;11:7-21. doi: 10.2147/PGPM.S149803. eCollection 2018.

13.

The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction.

Zastrozhin MS, Grishina EA, Ryzhikova KA, Smirnov VV, Savchenko LM, Bryun EA, Sychev DA.

Pharmgenomics Pers Med. 2017 Dec 28;11:1-5. doi: 10.2147/PGPM.S144503. eCollection 2018.

14.

Ethiopian health care professionals' knowledge, attitude, and interests toward pharmacogenomics.

Abdela OA, Bhagavathula AS, Gebreyohannes EA, Tegegn HG.

Pharmgenomics Pers Med. 2017 Dec 5;10:279-285. doi: 10.2147/PGPM.S145336. eCollection 2017.

15.

Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran.

Rizk M, Tüzmen Ş.

Pharmgenomics Pers Med. 2017 Nov 10;10:267-278. doi: 10.2147/PGPM.S87945. eCollection 2017. Review.

16.

Pharmacogenomics of sickle cell disease: steps toward personalized medicine.

Husain M, Hartman AD, Desai P.

Pharmgenomics Pers Med. 2017 Oct 19;10:261-265. doi: 10.2147/PGPM.S123427. eCollection 2017. Review.

17.

Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?

Rytkin E, Mirzaev KB, Grishina EA, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Giliarov MI, Andreev DA, Sychev DA.

Pharmgenomics Pers Med. 2017 Sep 18;10:243-245. doi: 10.2147/PGPM.S143250. eCollection 2017.

18.

Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients.

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA.

Pharmgenomics Pers Med. 2017 Sep 27;10:253-259. doi: 10.2147/PGPM.S141935. eCollection 2017.

19.

Pharmacogenomic testing: aiding in the management of psychotropic therapy for adolescents with autism spectrum disorders.

Bose-Brill S, Xing J, Barnette DJ, Hanks C.

Pharmgenomics Pers Med. 2017 Sep 25;10:247-252. doi: 10.2147/PGPM.S130247. eCollection 2017.

20.

ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine.

Piatkov I, Caetano D, Assur Y, Lau SL, Jones T, Boyages SC, McLean M.

Pharmgenomics Pers Med. 2017 Aug 28;10:235-242. doi: 10.2147/PGPM.S142314. eCollection 2017.

Supplemental Content

Loading ...
Support Center